Bioabsorbable Vascular Plug Seals Arteriotomies

A novel vascular closure device (VCD) provides a safe and predictable means for achieving immediate hemostasis following percutaneous femoral procedures.

The velox CD VCD is made from a proprietary AZ31 magnesium alloy, and is designed to absorb rapidly following a percutaneous transluminal coronary angioplasty (PTCA) procedure. The implant portion of the closure device consists of three bioabsorbable components: an intraluminal footplate, an extraluminal plug, and a wire that holds them together. The three components work in concert to mechanically seal the arteriotomy. While the implant's intraluminal portion dissolves within just 24 hours, the remainder is completely resorbed within two weeks.


The device is positioned using the PTCA guidewire for correct orientation; the guidewire is then removed. The easy-to-use, single-use implant is indicated for the closing of arteriotomies ranging in size from 5F to 8F, providing surgeons with a closure option that seals the vessel wall, thus avoiding the need for time-consuming manual compression and allowing for shorter patient time-to-ambulation. The single size velox CD is a product of Transluminal Technologies (Syracuse, NY, USA), and has received the European Community CE marking of approval.

“Velox CD is a true next generation vascular closure device that addresses the shortcomings of extant products with vastly improved implant delivery and bioabsorption technologies,” said Stephen Green, co-founder and president of Transluminal Technologies. “Transluminal will continue its commitment to innovation in interventional devices and improved patient outcomes.”

“Velox CD is the world's first metal-based bioabsorbable closure device that is simple to use and highly predictable for femoral access site hemostasis,” added Shing-Chiu Wong, MD, director of the cardiac catheterization laboratories at the New York Presbyterian - Weill Cornell Medical Center (New York, NY, USA), and a leading clinical participant in the velox CD clinical studies. “This innovation should prove to be a significant enhancement to the existing offerings.”

Related Links:
Transluminal Technologies
Animated Velox CD Operation